QuidelOrtho (QDEL) grants CEO 213,470 RSUs vesting 2027–2029

Rhea-AI Filing Summary

QuidelOrtho Corporation President and CEO Brian J. Blaser received a grant of 213,470 restricted stock units on January 30, 2026. Each unit represents the right to receive one share of QuidelOrtho common stock.

According to the vesting schedule, 71,156 shares will vest on January 30, 2027. The remaining 142,314 shares will vest in equal installments on January 30, 2028 and January 30, 2029, aligning the CEO’s compensation with longer-term company performance.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Blaser Brian J.

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	213,470	$0.00	--

Holdings After Transaction: Restricted Stock Units — 213,470 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. 71,156 shares will vest on January 30, 2027; the remaining 142,314 shares will vest in equal installments on January 30, 2028 and January 30, 2029.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Blaser Brian J.

(Last) (First) (Middle)

9975 SUMMERS RIDGE ROAD

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
QuidelOrtho Corp [ QDEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	01/30/2026		A		213,470		(2)	(2)	Common Stock	213,470	$0	213,470	D

Explanation of Responses:

1. Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock.

2. 71,156 shares will vest on January 30, 2027; the remaining 142,314 shares will vest in equal installments on January 30, 2028 and January 30, 2029.

Remarks:

	/s/ Jennifer Ahn, attorney-in-fact for Brian J. Blaser	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did QuidelOrtho (QDEL) report in this Form 4?

QuidelOrtho reported an equity grant to its CEO. President and CEO Brian J. Blaser received 213,470 restricted stock units on January 30, 2026, as disclosed in the Form 4 insider filing with the SEC.

How many restricted stock units were granted to QuidelOrtho CEO Brian J. Blaser?

The CEO was granted 213,470 restricted stock units. These derivative securities were awarded on January 30, 2026, at a price of $0 per unit, and are shown as directly owned following the reported transaction.

What is the vesting schedule for Brian J. Blaser’s 213,470 QuidelOrtho RSUs?

The RSUs vest in three annual stages. 71,156 shares will vest on January 30, 2027, and the remaining 142,314 shares will vest in equal installments on January 30, 2028 and January 30, 2029.

What does each restricted stock unit represent in the QuidelOrtho Form 4?

Each restricted stock unit equals one common share. The filing states that every RSU represents the right to receive one share of QuidelOrtho Corporation common stock, tying the award directly to the company’s equity.

Is Brian J. Blaser’s ownership in this QuidelOrtho Form 4 direct or indirect?

The reported ownership is direct. The Form 4 lists the 213,470 restricted stock units as directly owned by Brian J. Blaser, with no separate entity or indirect ownership structure referenced in the ownership field.

What role does Brian J. Blaser hold at QuidelOrtho (QDEL) in this filing?

He serves as President and CEO of QuidelOrtho. The Form 4 identifies Brian J. Blaser as an officer, specifically listing his title as President and CEO, and reports his newly granted restricted stock units.